Home > News > Company news > Da Xiang Biotech and Nikon signed a strategic cooperation agreement to jointly promote the development of organoid chip technology
Da Xiang Biotech and Nikon signed a strategic cooperation agreement to jointly promote the development of organoid chip technology
2023-04-25 3585

On April 12, 2022, Daxiang Biotech and Nikon jointly held a cutting-edge summit on the transformation and application of organoid chips in Shanghai, and signed a strategic cooperation agreement between the two sides during the conference to jointly promote the development of organoid chip technology.

Da Xiang Biotech is a pioneer and leader in the Chinese organ chip industry. This time, it has signed a strategic cooperation agreement with global optical technology and product giant Nikon to complement each other's advantages, deepen cooperation, and jointly empower the research and application transformation of organ chips.



Shanggu Gang

Nikon Precision Machine Director 


Zhou Yu

Daxiang  Biotech


The main leaders of both sides lit up the pillar of light and opened a new chapter in the cooperation between Daxiang and Nikon


The meeting invited Dr. Geng Xingchao from the Safety Evaluation Research Institute of the Chinese Academy of Food and Drug Control to bring a special report on "Organ Chip Technology and Drug Safety Evaluation Research" to everyone.

In the past two decades, with the emergence of a variety of new evaluation technologies and means, new drug evaluation strategies have become more comprehensive and scientific, but there are still many difficulties, such as cardiac toxicity evaluation, reproductive toxicity evaluation, genetic toxicity evaluation, carcinogenicity evaluation, etc.

Organoid chip can simulate human physiological structure, so it can better reflect the reaction of human diseases to drugs than animals.

In 2022, the Safety Assessment Institute of the Chinese People's Procuratorate reached a strategic partnership with Daxiang Biotech to jointly explore and promote the application of organoid chip technology in drug safety evaluation.


Subsequently, Dr. Ding Duanchen, the R&D director of Daxiang Biotech, introduced in more detail to the audience the construction of a disease physiological model based on organoid chips and its application in new drug development.

Compared with traditional 2D cell models and animal models, organoid models have many significant advantages.

In the evaluation of tumor drugs, the tumor organoid model co cultured with CAF has higher clinical consistency;

In the evaluation of drug liver toxicity, the positive prediction rate of liver like organ models is also much higher than that of traditional animal models.


In subsequent reports, Manager Lu Yingying of Nikon Company presented multiple high-definition beautiful images of organoid taken by the Daxiang Technology Laboratory using Nikon's new generation confocal imaging system, once again verifying the powerful optical imaging and image processing capabilities of a century old optical giant.


Beijing Yimiao Shenzhou, as one of the earliest innovative enterprises in China to use organoid on chips evaluation drugs, was also presented with a special report titled "When Solid Tumor CAR-T Development Encounters Organs" by its founder, Dr. Lu Xin'an.

Yimiao Shenzhou has applied organoid models to different research and development pipelines under its umbrella, such as screening the optimal CAR-T treatment plan and evaluating its efficacy.

Among them, the IND application for IM83 CAR-T cell injection, a CAR-T cell drug used for the treatment of advanced liver cancer, was officially accepted by CDE on April 11th, using a 3D tumor model for efficacy evaluation in collaboration with Daxiang Biotech.


In the final round table discussion session, multiple technical leaders from Roche, Tianjing Biotechnology, Jiutian Biotechnology, Merck Investment, Nikon Precision Machinery, and Daxiang Biotech gathered together to speak freely. We will conduct in-depth discussions and prospects from multiple dimensions, including the development of organoid chip technology, changes in domestic and foreign policy environments, and industrial applications in the field of new drug research and development.